BRCA1 and ovarian cancer: Monoallelic germline BRCA1/2 pathogenic variants (PV) substantially increase the risk of developing breast (BC) and/or ovarian cancer (OC), but at least 10% of BRCA1/2 tests result in a variant of unclassified/uncertain/unknown significance (VUS)1.